Levonorgestrel-releasing intrauterine system for treatment of adenomyosis

Objective Release of levonorgestrel intrauterine system(LNG-IUS;brand name:Mirena)in the treatment of adenomyosis with menorrhagia and dysmenorrhea clinical efficacy.Methods 65 cases of uterine adenomyosis induced menorrhagia and dysmenorrhea patients,in the period 4 to 7 days placed LNG-IUS,the line before and after comparison:in the LNG-IUS placed before and 3,6,12 months after placement,respectively,VRS by PBAC Comparison method and amount of menstruation,and pain scores,respectively,while serum CA125,menstrual day 3 serum estradiol(E2),follicle stimulating hormone(FSH),luteinizing hormone(LH)levels.Results Levonorgestrel intrauterine system placed 12 months after release,the amount of the PBAC law menstrual score by placing the former(119.6±61.0)decreased 3,6,12 months after the treatment time(55.1±22.8),(38.4±17.8),(19.6±8.5),and placed the former were statistically significant differences(P0.01);dysmenorrhea VRS score from before treatment(2.2±0.4)decreased(1.3±0.6),(0.5±0.2),(0.4 ±0.3),the differences were statistically significant(P0.01);serum CA125 decreased from(66±21) kU/L decreased(52±20) kU/L,(35±14) Ku/L,(22± 11) kU/L,the differences were statistically significant(P0.01);E2,FSH and LH and placed before the difference was not statistically significant(P0.05).Conclusion LNG-IUS treatment of adenomyosis and dysmenorrhea,menorrhagia due to significant effect.